Capivasertib

What Capivasertib Means in Everyday Medical Language

Capivasertib, also known by its brand name Truqap, is a targeted cancer drug used mainly to treat a certain kind of breast cancer. This breast cancer is hormone receptor-positive and HER2-negative, which means the cancer cells grow in response to hormones but do not have extra HER2 protein. Capivasertib works by blocking a protein called AKT that helps cancer cells grow and survive. It is taken by mouth and used together with another drug called fulvestrant, a hormone therapy.

Why Capivasertib Can Matter in Cancer Care

Some breast cancers have changes in specific genes—PIK3CA, AKT1, or PTEN—that can cause cancer cells to grow uncontrollably. Capivasertib targets these gene changes by blocking the AKT protein’s activity, which may slow or stop cancer growth. It is used when breast cancer has spread to other parts of the body and has come back or worsened during or after hormone therapy. Because it targets cancer cells more precisely than traditional chemotherapy, it may have different side effects and treatment schedules.

What Patients Might See or Hear About Capivasertib

Patients may hear about capivasertib during discussions about treatment options for advanced breast cancer or when considering clinical trials. Doctors usually test the cancer cells to check for gene changes in PIK3CA, AKT1, or PTEN before recommending capivasertib, as this helps predict if the drug might work. Patients might see the name Truqap on drug labels or medical records. Common side effects include diarrhea, nausea, fatigue, and changes in blood counts or blood sugar levels.

Where Capivasertib Might Appear in Care and Information

Capivasertib may be mentioned in treatment plans, drug information sheets, clinical trial descriptions, or medical reports. It is a newer drug approved in the United States and other countries for specific breast cancer types. Patients may also find information about it on trusted cancer websites or from their healthcare team.

What Capivasertib Does Not Automatically Mean

Having the gene changes that capivasertib targets does not guarantee the drug will work for every patient. Also, capivasertib is not chemotherapy but a targeted therapy, so it is not a cure and is approved only for certain breast cancers. It is still being studied for other cancers, but its use outside approved types is experimental. Patients should not assume it is suitable for all breast cancers or other cancers without specific testing and doctor advice.

Practical Questions to Ask Your Care Team

Patients can ask if their tumor has been tested for PIK3CA, AKT1, or PTEN gene changes and whether capivasertib might be an option. It is helpful to discuss how capivasertib works with other treatments, possible side effects, how it is taken, and what monitoring is needed during treatment. Asking about clinical trials involving capivasertib may also be useful.

Understanding Capivasertib in Context

Capivasertib is one option among many in breast cancer care, especially for cancers with certain gene changes. It is part of a growing group of targeted therapies that aim to personalize treatment. Decisions about using capivasertib should always be made with a healthcare team, considering each person’s unique cancer and health situation.

Safety and Next Steps

This information is educational and does not replace medical advice. If you or a loved one is facing breast cancer treatment, talking openly with your healthcare team about capivasertib can help you understand if it might be right for you. Your care team can explain testing, treatment plans, side effects, and clinical trial options to support your decisions.